With a goal of making precision medicine the standard of care at health systems, Sema4 struck a nearly $800 million deal with CM Life Sciences to go public. The company, which offers tools that combine genomic and clinical data to glean patient care insights, will get $500 million in cash proceeds to grow its business.
